medigraphic.com
Colegio de Medicina Interna de México.

2007, Número 4

<< Anterior Siguiente >>

Med Int Mex 2007; 23 (4)


Progresos en la insuficiencia cardiaca

Romero CAJ, Carles ZJM, Hernández OEB

Idioma: Español
Referencias bibliográficas: 61
Paginas: 321-329
Archivo PDF: 175.15 Kb.


RESUMEN

La insuficiencia cardiaca predomina en los adultos mayores y es un síndrome de alta prevalencia, alta mortalidad y altos costos. Este artículo discute los principales progresos sobre esta enfermedad, como los nuevos criterios definitorios, los tipos de disfunción, la nueva clasificación por estadios y los progresos en el conocimiento de la fisiopatología, el diagnóstico y el tratamiento.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Davies RC, Hobbs FDR, Lip GYH. ABC of heart failure. History and epidemiology. BMJ 2000;320:39-42.

  2. Aldama López G, Piñeiro Portela M, Campo Pérez Esteban P. Insuficiencia cardiaca: concepto, epidemiología, clasificación, etiología y fisiopatología. Medicine 2005;9(35):2279-90.

  3. Romero Cabrera AJ. Insuficiencia cardiaca en el anciano. Geriatrianet.com. Revista Electrónica de Geriatría 2002; 4(1): 1-30. URL disponible en http://www.geriatrianet.com/numero6/ privado6/geriatriaarticulo 2002_1.html.

  4. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol 1993;22:6A-13.

  5. Abdelhafis AH. Heart failure in older people: causes, diagnosis and treatment. Age Ageing 2000;31:29-36.

  6. Rodríguez Artalejo F, Banegas Banegas JR, Guallar Castillón P. Epidemiología de la insuficiencia cardiaca. Rev Esp Cardiol 2004;57:163-70.

  7. Manzano L, Sánchez Mateo D, Rodríguez González P. La insuficiencia cardiaca en la práctica asistencial del internista. Rev Clin Esp 2005;205(7):305-6.

  8. Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348(20):2007-18.

  9. Basile JN. Heart failure: a three-article symposium. Postgrad Med 2003;113(3):50.

  10. Cowie MR, Fox KF, Wood DA. Hospitalization of patients with heart failure: a population-based study. Eur Heart J 2002;23:877-85.

  11. Lee DS, Mamdani MM, Austin PC. Trends in heart failure outcomes and pharmacotherapy: 1992 to 2000. Am J Med 2004;116:581-89.

  12. Bleumink GS, Knetsch AM, Sturkenboom MC. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. Eur Heart J 2004;25:1614-19.

  13. Roger VL, Weston SA, Redfield MM. Trends in heart failure incidence and survival in a community-based population. JAMA 2004;292:344-50.

  14. Osca Asensi J, Cuéllar de León AJ. Factores pronósticos en la insuficiencia cardiaca. SEMERGEN 2004;30(9):437-43.

  15. McMurray JJV, Pfeffer MA. Heart failure. Lancet 2005;365:1877-89.

  16. Hunt SA, Abraham WT, Chin MH, Feldman AM, et al. ACA/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult–summary article. J Am Coll Cardiol 2005;46:1116-43.

  17. Negrín JE, Cordiés L, Roselló N, Sánchez J, Negrín JA. Insuficiencia cardiaca crónica. Rev Cubana Med 2001;40(3):195-211.

  18. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004;43:317-27.

  19. Kitzman DW, Little WC, Burbaker PH, Anderson RT, et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002;288:2144-50.

  20. Cleland JG, Swedberg K, Follath F, Komajda M, et al. The Euro Heart Failure Survey Program–a survey on the quality of care among patients with heart failure in Europe. Part 1: patients characteristics and diagnosis. Eur Heart J 2003;24:442-63.

  21. McMurray JJV, Pfeffer MA. The year in heart failure. J Am Coll Cardiol 2004;44:2398-405.

  22. Zile MR. Heart failure with preserved ejection fraction: is this diastolic failure? J Am Coll Cardiol 2003;41:1519-22.

  23. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure–abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004;350:1953-9.

  24. Kass DA, Bronzwaer JGF, Paulus WJ. What mechanisms underlie diastolic dysfunction in heart failure. Circulation Res 2004;94:1533-43.

  25. Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003;289:194-202.

  26. Lenzen MJ, Scholte OP, Reimer WJ, Boersma E, et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the Euro Heart Failure Survey. Eur Heart J 2004;25(14):1214-20.

  27. Masoudi FA, Hawanek EP, Smith G, Fish RH, et al. Gender, age and heart failure with preserved ventricular systolic function. J Am Coll Cardiol 2003;41:217-23.

  28. European Study Group on Diastolic Heart Failure. How to diagnose diastolic heart failure. Eur Heart J 1998;19:990-1003.

  29. Pantilat SZ, Steimle AE. Palliative care for patients with heart failure. JAMA 2004;291:2476-82.

  30. Gibelin P. An evaluation of symptom classification systems used for the assessment of patients with heart failure in France. Eur J Heart Fail 2001;3:739-46.

  31. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet 2006;367:356-67.

  32. Pérez Villa F. Avances en el tratamiento de la insuficiencia cardiaca. Med Clin (Barc) 2004;123(4):149-53.

  33. Kaluski E, Kobrin I, Zimlichman R, Marmor A, et al. RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double blind, placebo-controlled study. J Am Coll Cardiol 2003;41:204-10.

  34. Mann DL. Inflammatory mediators and the failing heart. Past, present, and the foreseeable future. Circ Res 2002;91:988-98.

  35. Goetze JP, Kastrup J, Rehfeld JF. The paradox of increased natriuretic hormones in congestive heart failure patients: Does the endocrine heart also fail in heart failure? Eur Heart J 2003;24:1471-2.

  36. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 2005;330:625-33.

  37. De Lemos JA, McGuire DK, Drazner MH. B-type natriuretic in cardiovascular disease. Lancet 2003;362:316-22.

  38. Muñoz Rivas N. Manejo del paciente con insuficiencia cardiaca aguda e insuficiencia cardiaca refractaria al tratamiento convencional. JANO 2005;21(1580):49-55.

  39. Ribera Casado JM. Protocolo de evaluación y tratamiento de la insuficiencia cardiaca en el paciente anciano. Medicine 2003;8(109):5857-9.

  40. Garrido Bravo JP, Rodríguez Fernández JA, García de Lara J, Castro Beiras A. Tratamiento de la insuficiencia cardiaca crónica. Medicine 2005;9(35):2318-26.

  41. Pitt B, Zannad F, Remme WJ, Cody R, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.

  42. Pitt B, Remme W, Zannad F, Neaton J, et al. Eplerenone, a selective aldosterone blocker in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.

  43. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316(23):1429-35.

  44. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325(5):293-302.

  45. Cohn JN, Johnson G, Ziesche S, Cobb F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325(5):303-10.

  46. Pfeiffer MA, Braunwald E, Moye LA. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. The SAVE Investigators. N Engl J Med 1992;327(10):669-77.

  47. Pitt B, Poole-Wilson P, Segal R, Martinez FA, et al. Effects of losartan vs captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study–ELITE II. J Card Fail 1999;5(2):146-54.

  48. Krum H, Carson P, Fassang C. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: result from Val-HeFT. Eur J Heart Fail 2004;6:937-45.

  49. Mc Murray JJ, Ostergreen J, Swedberg K. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71.

  50. Packer M, Bristow MR, Cohn JN, Colucci WS, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334(21):1349-55.

  51. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. CIBIS-II Investigators and Committee. Lancet 1999;353(9146):9-13.

  52. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353(9169):2001-7.

  53. Packer M, Fowler MB, Roecker EB, Coats AJS, et al. Effect of carvedilol on the mortality patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (Copernicus) Study. Circulation 2002;106:2194-99.

  54. Poole-Wilson P, Swedberg K, Cleland J, Lenarda A, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial. Lancet 2003;362:7-13.

  55. Ahmed A. Role of digoxin in heart failure in older adults. Geriatrics and Aging 2002;5(7):48-52.

  56. Garg R, Gorlin R, Smith T, Yusuf S. The effect of digoxin on mortality in patients with heart failure. The Digitalis Investigation Group (DIG). N Engl J Med 1997;336:525-33.

  57. Cohn JN, Jhonson G, Ziesche S. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.

  58. Kaluski E, Kobrin I, Zimlichman R, Marmor A, et al. RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double blind, placebo-controlled study. J Am Coll Cardiol 2003;41:204-10

  59. Mann D. Inflammatory mediators and the failing heart. Past, present, and the foreseeable future. Circ Res 2002;91:988-98.

  60. Mc Kelvie R. Cardiovascular disorders: heart failure. Interventions. Clinical Evidence. BMJ Publishing Group Limited 2006. URL disponible en: http://www.clinicalevidence.com. Web publication date: 01/04/2006.

  61. Bradley D, Bradley E, Baughman K, Berger R, et al. Cardiac resynchronization and death from progressive heart failure. A meta-analysis of randomized controlled trials. JAMA 2003;289:730-40.




2020     |     www.medigraphic.com